MALDI-TOF MS Identifies Oomycete Causing Pythiosis
|
By LabMedica International staff writers Posted on 12 Dec 2018 |

Image: The UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Photo courtesy of Bruker Daltonics).
Pythiosis is an invasive, difficult-to-treat, life-threatening infectious disease caused by Pythium insidiosum, a member of the unique group of fungus-like microorganisms called oomycetes. The disease has been increasingly reported worldwide.
In the past decade, the matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) has emerged as a novel and powerful diagnostic tool for facilitating the clinical identification of many pathogenic microorganisms, including bacteria and fungi.
Scientists at the Mahidol University (Bangkok, Thailand) isolated a total of 13 strains of P. insidiosum, isolated from eight humans and five animals with pythiosis, from different geographic locations. All organisms were maintained on Sabouraud dextrose agar at 25 °C. Several small portions of a colony of each organism were transferred to a 50-mL flask containing 10 mL Sabouraud dextrose broth, and incubated at 37 °C for one week, before harvesting fungal material for protein extraction.
Protein was extracted from harvested organisms and was spotted onto a clean ground steel target plate in 40 replicates (for generating a MALDI-TOF MS database of P. insidiosum) or five replicates (for assessing the MALDI-TOF MS for identification of P. insidiosum), air dried at room temperature before being processed. After the matrix solution was air dried at room temperature, the sample was promptly analyzed, using a Bruker ultrafleXtreme mass spectrometer. Genomic DNA (gDNA) templates were extracted from the organisms and subjected to single nucleotide polymorphism-based multiplex polymerase chain reaction (PCR).
The team reported that the MALDI-TOF MS accurately identified all 13 P. insidiosum strains tested, at the species level. Mass spectra of P. insidiosum did not match any other microorganisms, including fungi (i.e., Aspergillus species, Fusarium species, and fungal species of the class Zygomycetes), which have similar microscopic morphologies with this oomycete. MALDI-TOF MS- and rDNA sequence-based biotyping methods consistently classified P. insidiosum into three groups: Clade-I (American strains), II (Asian and Australian strains), and III (mostly Thai strains).
The authors concluded that MALDI-TOF MS has been successfully used for identification and biotyping of P. insidiosum. The obtained mass spectral database allows clinical microbiology laboratories, well equipped with a MALDI-TOF mass spectrometer, to conveniently identify P. insidiosum, without requiring any pathogen-specific reagents (i.e., antigen, antibody or primers). The study was published in the December 2018 issue of the International Journal of Infectious Diseases.
Related Links:
Mahidol University
In the past decade, the matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) has emerged as a novel and powerful diagnostic tool for facilitating the clinical identification of many pathogenic microorganisms, including bacteria and fungi.
Scientists at the Mahidol University (Bangkok, Thailand) isolated a total of 13 strains of P. insidiosum, isolated from eight humans and five animals with pythiosis, from different geographic locations. All organisms were maintained on Sabouraud dextrose agar at 25 °C. Several small portions of a colony of each organism were transferred to a 50-mL flask containing 10 mL Sabouraud dextrose broth, and incubated at 37 °C for one week, before harvesting fungal material for protein extraction.
Protein was extracted from harvested organisms and was spotted onto a clean ground steel target plate in 40 replicates (for generating a MALDI-TOF MS database of P. insidiosum) or five replicates (for assessing the MALDI-TOF MS for identification of P. insidiosum), air dried at room temperature before being processed. After the matrix solution was air dried at room temperature, the sample was promptly analyzed, using a Bruker ultrafleXtreme mass spectrometer. Genomic DNA (gDNA) templates were extracted from the organisms and subjected to single nucleotide polymorphism-based multiplex polymerase chain reaction (PCR).
The team reported that the MALDI-TOF MS accurately identified all 13 P. insidiosum strains tested, at the species level. Mass spectra of P. insidiosum did not match any other microorganisms, including fungi (i.e., Aspergillus species, Fusarium species, and fungal species of the class Zygomycetes), which have similar microscopic morphologies with this oomycete. MALDI-TOF MS- and rDNA sequence-based biotyping methods consistently classified P. insidiosum into three groups: Clade-I (American strains), II (Asian and Australian strains), and III (mostly Thai strains).
The authors concluded that MALDI-TOF MS has been successfully used for identification and biotyping of P. insidiosum. The obtained mass spectral database allows clinical microbiology laboratories, well equipped with a MALDI-TOF mass spectrometer, to conveniently identify P. insidiosum, without requiring any pathogen-specific reagents (i.e., antigen, antibody or primers). The study was published in the December 2018 issue of the International Journal of Infectious Diseases.
Related Links:
Mahidol University
Latest Molecular Diagnostics News
- Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
- Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
- Liquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis
- Newborn Screening Program Adds Spinal Muscular Atrophy Testing Across England
- Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
- Liquid Biopsy Assay Enriches Tumor DNA for Early Detection and Monitoring
- Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
- Point-of-Care Multiplex PCR Test Submitted to FDA for Flu A/B and RSV Detection
- New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance
- Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
- Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
- AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
- Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
- Polygenic Risk Score Test Estimates Inherited Coronary Artery Disease Risk
- AI Tool Improves Long-Read Detection of Cancer Mutations
- FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Channels
Clinical Chemistry
view channel
Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more
New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
Oral squamous cell carcinoma can be difficult to triage at the point of care, resulting in frequent biopsies of lesions that ultimately prove benign. Limited access to pathology services in many communities... Read moreMolecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







